Efficacy of oral gabapentin on pain intensity in patients with acute low back pain patients

To detect the efficacy of oral gabapentin on pain intensity in patients with acute low back pain patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201303096480N4

Enrollment

100

Registered

2013-04-20

Start date

2013-03-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute back pain. Low back pain

Interventions

Intervention 1: Control group: Two weeks undertreatment by Naproxen tablets(500mg) twice each day and placebo daily two tabets. Intervention 2: Interventional group: Two weeks undertreatment by Naprox

Treatment - Drugs

Control group: Two weeks undertreatment by Naproxen tablets(500mg) twice each day and placebo daily two tabets

Interventional group: Two weeks undertreatment by Naproxen tablets(500mg)twice each day and Gabapentin(100mg) daily two talets

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. No systematic disease (diabetes or thyroid disease); infectious diseases(brucellosis and tuberculosis); vascular disease; clotting disorder(hemophilia); structural disorders ( scoliosis and Spondylolysthesis). 2. The neurologic symptoms (positive SLR, cross SLR, loss of tendon reflexes and sensation. 3. Aged between 20-24 years 4. Complained of acute pain (less than 4 weeks). 5. Patients’ willingness to participate in the study . Exclusion criteria : 1-Corticosteroid injections in the back region or other parts of the body in the 3 months before the study and during the study. 2- No satisfaction to continue treatment. 3-INividuals who consume narcotic drugs 4- The history of recurring back pain for more than 4 times in a year. 5- Consumption multiple medications for other diseases sleep medications, relaxant, acetaminophen and NSAIDs).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Before intervention, 15th, 8th, 30th day after intervention. Method of measurement: VAS standard Questionaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Morteza Dehghan

Shahrekord University OF Medical Sciences

dehghan_mortaza@yahoo.com+98 38 1226 4835

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026